chr12-57755601-C-G

Variant summary

Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_Strong

The NM_138396.6(MARCHF9):​c.73C>G​(p.Arg25Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000446 in 1,355,750 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.00040 ( 0 hom., cov: 29)
Exomes 𝑓: 0.00045 ( 1 hom. )

Consequence

MARCHF9
NM_138396.6 missense

Scores

1
18

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 1.07

Publications

1 publications found
Variant links:
Genes affected
MARCHF9 (HGNC:25139): (membrane associated ring-CH-type finger 9) MARCH9 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH enzymes add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments. MARCH9 induces internalization of several membrane glycoproteins and directs them to the endosomal compartment (Bartee et al., 2004 [PubMed 14722266]; Hoer et al., 2007 [PubMed 17174307]).[supplied by OMIM, Apr 2010]
CDK4 (HGNC:1773): (cyclin dependent kinase 4) The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008]
CDK4 Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
  • malignant pancreatic neoplasm
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -4 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.020781755).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MARCHF9NM_138396.6 linkc.73C>G p.Arg25Gly missense_variant Exon 1 of 4 ENST00000266643.6 NP_612405.2
MARCHF9XM_047429894.1 linkc.73C>G p.Arg25Gly missense_variant Exon 1 of 3 XP_047285850.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MARCHF9ENST00000266643.6 linkc.73C>G p.Arg25Gly missense_variant Exon 1 of 4 1 NM_138396.6 ENSP00000266643.5 Q86YJ5-1
CDK4ENST00000552862.1 linkc.-20+331G>C intron_variant Intron 1 of 2 3 ENSP00000446763.1 F8W1L8
MARCHF9ENST00000552279.1 linkn.-127C>G upstream_gene_variant 2

Frequencies

GnomAD3 genomes
AF:
0.000398
AC:
60
AN:
150604
Hom.:
0
Cov.:
29
show subpopulations
Gnomad AFR
AF:
0.0000728
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000592
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000625
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000670
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000922
AC:
20
AN:
21702
AF XY:
0.000976
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00151
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000902
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000452
AC:
545
AN:
1205046
Hom.:
1
Cov.:
31
AF XY:
0.000466
AC XY:
275
AN XY:
590382
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
24004
American (AMR)
AF:
0.000647
AC:
8
AN:
12356
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
17974
East Asian (EAS)
AF:
0.00
AC:
0
AN:
27174
South Asian (SAS)
AF:
0.00108
AC:
57
AN:
52916
European-Finnish (FIN)
AF:
0.0000326
AC:
1
AN:
30718
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
3350
European-Non Finnish (NFE)
AF:
0.000467
AC:
461
AN:
988130
Other (OTH)
AF:
0.000372
AC:
18
AN:
48424
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
28
56
83
111
139
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000398
AC:
60
AN:
150704
Hom.:
0
Cov.:
29
AF XY:
0.000381
AC XY:
28
AN XY:
73524
show subpopulations
African (AFR)
AF:
0.0000726
AC:
3
AN:
41308
American (AMR)
AF:
0.000591
AC:
9
AN:
15218
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3438
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5084
South Asian (SAS)
AF:
0.000626
AC:
3
AN:
4794
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10426
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
286
European-Non Finnish (NFE)
AF:
0.000670
AC:
45
AN:
67156
Other (OTH)
AF:
0.00
AC:
0
AN:
2084
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.494
Heterozygous variant carriers
0
3
5
8
10
13
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000253
Hom.:
0
Bravo
AF:
0.000355
ExAC
AF:
0.0000274
AC:
1

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Jul 06, 2021
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.73C>G (p.R25G) alteration is located in exon 1 (coding exon 1) of the MARCH9 gene. This alteration results from a C to G substitution at nucleotide position 73, causing the arginine (R) at amino acid position 25 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.066
BayesDel_addAF
Benign
-0.59
T
BayesDel_noAF
Benign
-0.65
CADD
Benign
17
DANN
Benign
0.76
DEOGEN2
Benign
0.019
T
Eigen
Benign
-1.1
Eigen_PC
Benign
-1.1
FATHMM_MKL
Benign
0.17
N
LIST_S2
Benign
0.51
T
M_CAP
Benign
0.025
D
MetaRNN
Benign
0.021
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.90
L
PhyloP100
1.1
PrimateAI
Pathogenic
0.85
D
PROVEAN
Benign
-0.81
N
REVEL
Benign
0.055
Sift
Benign
0.17
T
Sift4G
Benign
0.54
T
Polyphen
0.0010
B
Vest4
0.18
MutPred
0.28
Gain of catalytic residue at G21 (P = 0.0033);
MVP
0.18
MPC
1.5
ClinPred
0.015
T
GERP RS
1.3
PromoterAI
0.0056
Neutral
Varity_R
0.096
gMVP
0.24
Mutation Taster
=69/31
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs758113214; hg19: chr12-58149384; API